Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interventional, Multicenter, Open-label, Randomized, Non-comparative Trial Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses

Next Previous
Search
Trial Profile

Interventional, Multicenter, Open-label, Randomized, Non-comparative Trial Evaluating the Safety, in Terms of HBV Virological Control at 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected With the HIV-1 and HBV Viruses

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atazanavir/lamivudine/ritonavir/tenofovir (Primary) ; Atazanavir/ritonavir (Primary) ; Bictegravir (Primary) ; Cobicistat/elvitegravir (Primary) ; Darunavir/ritonavir (Primary) ; Dolutegravir (Primary) ; Doravirine (Primary) ; Efavirenz (Primary) ; Emtricitabine (Primary) ; Emtricitabine/rilpivirine/tenofovir alafenamide (Primary) ; Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary) ; Emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Etravirine (Primary) ; Lamivudine (Primary) ; Lamivudine/tenofovir alafenamide (Primary) ; Lamivudine/tenofovir-disoproxil-fumarate (Primary) ; Raltegravir (Primary) ; Rilpivirine (Primary) ; Tenofovir alafenamide (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms BI-LIGHT

    • Most Recent Events

    • 03 Feb 2025 Planned initiation date changed from 1 Oct 2024 to 1 Feb 2025.
    • 20 Aug 2024 Planned End Date changed from 28 Feb 2027 to 30 Sep 2027.
    • 20 Aug 2024 Planned primary completion date changed from 28 Feb 2027 to 30 Sep 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top